Cleveland Biolabs
Cleveland BioLabs, Inc.(Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc.
7-day free trial · no credit card
Verified contacts
15
available on Kipplo
LinkedIn employees
24
51 to 200 range
Open roles
—
no listings
Distinct roles
13
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 15 verified contacts at Cleveland Biolabs
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
15 contacts with verified email or phone · masked until revealed.
- AS
Alexander Shakhov
Director · General Business & Management
EmailPhone - MM
Mimi Mieritz
Clinical Trial Manager · Research & Development
EmailPhone - RM
Ratan Maitra
Project Manager · Science
EmailPhone - TB
Tami Bartels
Building Manager Sr Admin Assistant · Operations
EmailPhone
Showing 4 of 15 verified contacts
Top roles at Cleveland Biolabs
13 distinct titles indexed · top 10 shown.
- 2chemist
- 1()
- 1a o
- 1administrator, project manager
- 1building manager sr admin assistant
- 1chair of the board of directors
- 1clinical trial manager
- 1director
- 1director clinical development
- 1director of business development
- +3more titles
Sign up to unlock all 15 contacts at Cleveland Biolabs
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 15 verified contacts at Cleveland Biolabs
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.